Heinz-Josef Lenz

Heinz-Josef Lenz

University of Southern California

H-index: 122

North America-United States

About Heinz-Josef Lenz

Heinz-Josef Lenz, With an exceptional h-index of 122 and a recent h-index of 79 (since 2020), a distinguished researcher at University of Southern California, specializes in the field of GI Oncology, Molecular Characterization, Early Drug Development, colon cancer, oncology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Plant-based diet and survival among patients with metastatic colorectal cancer: Findings from CALGB/SWOG 80405 (Alliance)

An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal …

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized …

A phase 1b/2 clinical study of onvansertib in combination with FOLFIRI/bevacizumab revealed a new role of PLK1 in regulating the hypoxia pathway in KRAS-mutant colorectal cancer

Gender specific role of LMTK3 in neuronal-tumor microenvironment crosstalk in CRC

CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value

Tissue factor: A link between metastatic colorectal cancer and thrombosis in patients in the CALGB (Alliance)/SWOG 80405 trial.

Repurposing dihydroergotamine mesylate as a potential MCL-1 inhibitor and its antitumor effect in pancreatic cancer cells

Heinz-Josef Lenz Information

University

Position

___

Citations(all)

81511

Citations(since 2020)

35852

Cited By

58178

hIndex(all)

122

hIndex(since 2020)

79

i10Index(all)

616

i10Index(since 2020)

381

Email

University Profile Page

Google Scholar

Heinz-Josef Lenz Skills & Research Interests

GI Oncology

Molecular Characterization

Early Drug Development

colon cancer

oncology

Top articles of Heinz-Josef Lenz

Plant-based diet and survival among patients with metastatic colorectal cancer: Findings from CALGB/SWOG 80405 (Alliance)

Cancer Research

2024/3/22

En Cheng
En Cheng

H-Index: 4

Chao Ma
Chao Ma

H-Index: 3

Heinz-Josef Lenz
Heinz-Josef Lenz

H-Index: 72

An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal …

2024/1/20

Heinz-Josef Lenz
Heinz-Josef Lenz

H-Index: 72

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized …

Journal for ImmunoTherapy of Cancer

2024

A phase 1b/2 clinical study of onvansertib in combination with FOLFIRI/bevacizumab revealed a new role of PLK1 in regulating the hypoxia pathway in KRAS-mutant colorectal cancer

Cancer Research

2024/3/22

Anju Karki
Anju Karki

H-Index: 6

Heinz-Josef Lenz
Heinz-Josef Lenz

H-Index: 72

Gender specific role of LMTK3 in neuronal-tumor microenvironment crosstalk in CRC

Cancer Research

2024/3/22

Tissue factor: A link between metastatic colorectal cancer and thrombosis in patients in the CALGB (Alliance)/SWOG 80405 trial.

2024/1/20

Repurposing dihydroergotamine mesylate as a potential MCL-1 inhibitor and its antitumor effect in pancreatic cancer cells

Cancer Research

2024/3/22

Sexual dysfunction among early-onset colorectal cancer survivors: Sex-specific correlates of sexual health discussions between patients and providers

Cancer Causes & Control

2024/1

Heinz-Josef Lenz
Heinz-Josef Lenz

H-Index: 72

Molecular and immune landscape by cyclin dependent kinase (CDK) 4/6 expression and TP53 mutational status in mismatch repair deficient/microsatellite instability-high (dMMR/MSI …

2024/1/20

A compound targeting the circadian clock protein CRY2 enhances therapeutic efficacy of bevacizumab in a colorectal cancer (CRC) xenograft model

Cancer Research

2024/3/22

Determinants of generalized self-efficacy and genetic knowledge among Hispanic/Latino colorectal cancer patients participating in ENLACE: A Cancer Moonshot Study

Cancer Research

2024/3/22

Heinz-Josef Lenz
Heinz-Josef Lenz

H-Index: 72

Characterization of the cachexia pathway in pancreatic ductal adenocarcinoma.

2024/1/20

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status

ESMO Gastrointestinal Oncology

2024/6/1

Identification and characterization of immunogenic neoantigens in biliary cancer (BC) and pancreatic cancer (PC).

2024/1/20

Structure-based screening for potential ROR1 inhibitors and their potential as antitumor agents in pancreatic cancer cells

Cancer Research

2024/3/22

Differential responses to immune checkpoint inhibitors are governed by diverse mismatch repair gene alterations

Journal of Experimental & Clinical Cancer Research

2022/4/2

Genome-wide association study (GWAS) and novel prognostic markers in metastatic colorectal cancer (mCRC).

2024/1/20

See List of Professors in Heinz-Josef Lenz University(University of Southern California)

Co-Authors

academic-engine